In this week's EuroBiotech Report, GW’s proof-of-concept trial faIls, Arix hooks up with Ipsen, Medigene trial gets green light and more.
In our EuroBiotech roundup this week, biotechs file to raise $300 million, Minoryx spins off platform and Galapagos, MorphoSys post clinical data.
The careful optimization of tumor-bearing humanized models leads to highly useful preclinical immuno-oncology platforms for accelerated immunotherapy…
Raxone is currently in a phase 3 study on DMD patients who are taking glucocorticoids.
While the trial linked GWP42006 to around a 40% drop in focal seizures, the placebo triggered a similarly sharp decline.
Takeda has added another early-stage research partnership as it reboots its R&D operations, this time teaming with two Seattle-based academic centers.
Kite will use the ZFN gene editing platform to create next-generation, off-the-shelf CAR-T therapies to cement its position in the cell therapy space.
With the new financing, Kallyope plans to move its pipeline programs toward the clinic and hire another 16 people.
John Davis, who headed early clinical development at Pfizer, joined Magenta Therapeutics.
Months after raising a $107 million series C, Arcus Biosciences has filed for a $100 million IPO.
Medigene has been given a green light in Germany to start human trials of MDG1011, the lead candidate to come out of its modified T-cell program.